We have shown that collagen type XI alpha 1 (COL11A1) promotes ovarian cancer progression and is associated with chemoresistance to cisplatin and paclitaxel in ovarian cancer cells. Here, we demonstrate how COL11A1 regulates twist family basic helix-loop-helix transcription factor 1-related protein 1 (TWIST1) to induce chemoresistance and inhibit apoptosis in ovarian cancer cells. Small interfering RNA-mediated reduction in COL11A1 protein levels increased the chemosensitivity to cisplatin and paclitaxel via downregulated TWIST1 expression. TWIST1 messenger RNA levels positively associated with COL11A1 messenger RNA expression levels in ovarian tumors. High TWIST1 expression levels were significantly associated with a progression-free interval of 6 months (p 5 0.001) and death (p 5 0.040). In addition, patients with high TWIST1 mRNA levels had significantly shorter 5-year overall-survival (p 5 0.004) and progression-free survival (p 5 0.009) rates, compared to patients with low TWIST1 levels. Increased TWIST1 expression caused by COL11A1-induced transcription of the inhibitor of nuclear factor kappa B kinase subunit beta (IKKb) gene occurred via increased SP1 phosphorylation and binding to the IKKb promoter. COL11A1-mediated nuclear factor-kappa B activation, via transcriptional activation of IKKb, promoted TWIST1, Mcl-1, and GAS6 expression, which were associated with chemoresistance and anti-apoptosis in ovarian cancer cells. We suggest that IKKb and TWIST1 can potentially be targeted in patients with COL11A1-positive ovarian cancer.
Epithelial ovarian carcinoma (EOC) is the most lethal gynecological malignancy. 1 Despite standard treatment including cytoreductive surgery followed by combination carboplatin and paclitaxel chemotherapy, many EOC patients eventually relapse, develop chemoresistant tumors, and die from the disease. 2 Therefore, it is important to identify markers that predict responsiveness to chemotherapy, which may enable the development of therapeutic biomarkers aimed at overcoming chemoresistance. Several studies have been performed using gene microarrays to identify distinct genes expressed in chemoresistant EOC patients. [3] [4] [5] [6] Previously, we analyzed the expression profiles of 60 epithelial ovarian cancer tissue samples obtained during the first cytoreductive surgery to identify genes associated with responses to chemotherapy and survival. Microarray analysis of the tissue samples showed that 47 genes (30 upregulated and 17 downregulated) were differentially expressed between chemoresistant and chemosensitive tumors ( Table 1 in our 2015 Oncotarget article   7 ). Collagen type XI alpha 1 (COL11A1) and twist family basic helix-loop-helix transcription factor 1 (TWIST1) were among the most highly upregulated genes in chemoresistant tumors.
7 COL11A1
belongs to the collagen family, which is a major component of the interstitial extracellular matrix. Our previous findings indicated that COL11A1 may promote tumor aggressiveness by upregulating the TGF-b1/MMP3 axis and that animal xenografts with upregulated COL11A1 expression showed enhanced lung metastasis. 8 COL11A1 expression is also associated with chemoresistance to cisplatin and paclitaxel. In contrast to chemosensitive cells, we found that cisplatin enhanced c/EBPb-and COL11A1-induced Akt-PDK1 binding in chemoresistant cells, resulting in attenuated PDK1 ubiquitination and degradation and protection of the cells from cytotoxic insults. 7 However, the mechanisms by which COL11A1 increase chemoresistance are not well understood.
TWIST1 is a highly evolutionally conserved basic helixloop-helix transcriptional factor that functions as a major regulator of gastrulation and mesodermal development. 9 The role of TWIST1 in tumor formation and progression is an active area of research and its important role is becoming increasingly evident. TWIST may affect the p53 tumorsuppressor pathway 10 and positively regulates the epithelial mesenchymal transition and HIF1a/TWIST/E-cadherin pathways, which correlates with high cancer aggressiveness and poor survival rates. 9 In addition, TWIST1 upregulation was responsible for the development of acquired paclitaxel resistance in nasopharyngeal carcinoma cells 11 and cisplatin resistance in ovarian cell lines. 9, 12 Analysis of our microarray data suggested that TWIST1 expression positively correlated with COL11A1 expression in ovarian cancer tumors. We thus tested the hypothesis that TWIST1-dependent COL11A1 expression influences resistance to anti-cancer drugs in ovarian cancer cells.
Materials and Methods

Study population
For the microarray analysis, we obtained ovarian cancer tissues from 60 patients with FIGO stage I-IV EOC who underwent comprehensive staging surgery or cytoreduction at our hospital between 2002 and 2010. 8 We further included 120 patients with EOC to study COL11A1 and TWIST1 expression levels in intra-operatively collected ovarian cancer specimens. A review of the medical records and pathology slides for these patients provided clinical characteristics, pathological diagnoses, and outcome information. The patients were followed up after treatment, and the date of the latest record retrieved was August 31, 2015. Both 5-year overall survival (OS) and progression-free survival (PFS) were calculated based on the date of diagnosis, and the progression-free interval (PFI) was measured to the date of last contact. EOC patients with PFI or > 6 months were divided into groups that were "resistant" or "sensitive" to platinum-based chemotherapy, respectively. This study was approved by our institutional review board (A-ER-105-017).
Quantitative reverse transcriptase PCR (RT-PCR)
Total RNA (5 lg) was used as the template in cDNAsynthesis reactions with random primers using Superscript III reverse transcriptase (Applied Biosystems). The resultant cDNAs were used (at a 1: 20 dilution) to detect the level of endogenous TWIST1 and COL11A1 mRNA expression by quantitative PCR (qPCR). Accurate quantitation was achieved using standard curves generated by serially diluting a known quantity of RNA from an in vitro transcription reaction and performing TaqMan qPCR with the dilution series along with the patient samples. Quantitative analysis of mRNA expression was performed using the Light Cycler V R 2.0 System (Roche Diagnostics GmbH). The primers and TaqMan probes used for the analyses were designed using the manufacturer's software, Primer Express. The following primers were used: COL11A1 (HS01097664), TWIST1 (HS00361186), GAS6 (HS01090305), L1CAM (HS01109748), and GAPDH (HS99999905). No-reverse-transcription (no-RT) control reactions were performed using 100 ng of total RNA from each individual sample as a template to ensure that the amplification was not due to DNA contamination. No signal was detected in the no-RT controls. Target gene mRNA expression was assessed by real-time RT-PCR. The reference gene GAPDH was used as the internal control for RNA quality. All quantitative analyses were performed in duplicate to assess the consistency of the results. The relative expression levels of the target gene, normalized to GAPDH expression, were calculated as DC t 5 C t (target) -C t (GAPDH). The ratio of the number of copies of the target gene mRNA to the number of copies of GAPDH was then calculated as 2 
Cells and media
The ES-2 and TOV-21G cell lines were purchased from the Bioresource Collection and Research Center of the Food Industry Research and Development Institute (Hsinchu, Taiwan). The OVCAR-3 and OVCAR-4 cell lines were purchased through the National Cancer Institute DTP tumor What's new? COL11A1 and TWIST1 were previously found to be among the most differentially upregulated genes in chemoresistant ovarian tumors. Here, the authors examined the role of COL11A1-dependent TWIST1 expression in chemoresistance and clinical outcome of epithelial ovarian carcinoma (EOC). TWIST1 upregulation caused by COL11A1-induced IKKb transcription occurred via increased SP1 binding to the IKKb promoter. COL11A1-mediated NF-jB activation, via IKKb transcriptional activation, promoted TWIST1 and Mcl-1 or GAS6 expression, which were associated with chemoresistance and apoptosis inhibition. EOC patients with TWIST1 overexpression had higher chemotherapy resistance and shorter survival, highlighting TWIST1 as an important chemoresistance and poor prognosis marker in EOC.
repository program. The human ovarian cancer cell lines A2780 and A2780CP70 were kindly provided by Dr. Hsu Keng-Fu (Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan). OVCAR-3, OVCAR-4, A2780 and A2780CP70 cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum. ES-2 cells were grown in McCoy's 5A medium supplemented with 10% fetal bovine serum. TOV-21G cells were grown in MCDB105/M199 medium supplemented with 10% fetal bovine serum. These cells were grown at 378C in a 5% carbon dioxide atmosphere. Cells were cultured and stored according to the supplier's instructions and used between passages 5 and 20. Once thawed, the cell lines were routinely authenticated approximately every 6 months, and the cells were last tested in March 2017 through cell morphology monitoring, growth curve analysis, species verification by isoenzymology and karyotyping, identity verification using short tandem repeat-profiling analysis, and contamination checks.
Plasmid constructs and transfection
Small interfering RNAs (siRNAs) directed against human COL11A1 (sc-72956-SH), TWIST1 (sc-38604-SH), IKKb (sc-35644-SH), and a non-targeting negative-control target (sc-108060) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Another independent siRNA targeting COL11A1 and a scrambled control siRNA were obtained from OriGene (SR300918 OriGene, Rockville, MD, USA). COL11A1 cDNA (BC117697 GE Healthcare) was cloned into the pCMV6-AC-GFP vector (PS100010 OriGene). TWIST1 (SC321467) and IKKb (RC219154) cDNA were purchased from OriGene. The NF-jB promoter was kindly provided by Prof. Hsiao-Sheng Liu (Department of Microbiology and Immunology, National Cheng Kung University, Tainan, Taiwan). NF-jB (p65), Mcl-1, and GAS6 siRNAs were purchased from the National RNAi Core Facility, Academia Sinica, Taiwan (Supporting Information Table 1 ). Expression plasmids were transfected into ovarian cancer cells using the HyFect TM DNA transfection reagent, according to the manufacturer's protocol (Leadgene Biomedical, Taiwan).
Western blot analysis
Proteins were extracted, and equal amounts were separated by 8-15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), as previously described. 8 
Cell fractionation
Cells were incubated in extraction buffer A (10 mM Tris-HCL [pH 8.0], 10 mM NaCl, 0.2% NP-40, 2 mM phenylmethylsulfonyl fluoride, 1 mg/mL pepstatin A, 0.2 mM leupeptin, 10 lg/mL aprotinin, 1 mM sodium vanadate, 1 mM nitrophenyl phosphate, and 5 mM benzamidine) for 30 min at 48C, followed by centrifugation at 3,000 rpm for 5 min at 48C. The supernatant was kept as the cytoplasmic extract. The pellet was washed with extraction buffer A, incubated in RIPA buffer for 30 min at 48C, and centrifuged at 13,000 rpm for 10 min at 48C. The supernatant was kept as the nuclear extract. Equal amounts of cytoplasmic and nuclear extracts were resuspended in SDS loading buffer with 2-mercaptoenthanol and boiled for 10 min. Equal amounts of proteins were separated by 8%-15% SDS-PAGE.
Antibodies and reagents
Antibodies against COL11A1 (GTX55142), a-tubulin (GTX62882) and phospho-SP1 (p-SP1, GTX50710) were obtained from GeneTex 
Plasmid construction and site-directed mutagenesis
The TWIST1 PCR product was cloned into the KpnI and XhoI sites of the pGL4 vector. Primers with the following sequences were used: forward 5 0 -GGTACCACTTCGAAAA GTCCCTCCTCCTC-3 0 and reverse 5 0 -CTCGAGTGGGCG AGAGCTGCAGACTTGG-3 0 . The resultant construct was confirmed by DNA sequencing. The IKKb PCR product was cloned into the KpnI and XhoI sites of the pGL4 vector. The resultant construct was confirmed by DNA sequencing. Sitedirected mutagenesis was used to generate COL11A1-400/-1 promoter constructs containing SP1 mutant-binding sites using complementary oligonucleotides (Supporting Information Table 2 ).
Luciferase reporter assays
Luciferase assays were conducted 48 hrs after transfection using the Dual-Luciferase Reporter Assay System (Promega). Normalized luciferase activity is reported as the ratio of luciferase activity to b-galactosidase activity.
Chromatin immunoprecipitation (ChIP) assays
Native protein-DNA complexes were cross-linked by treatment with 1% formaldehyde for 15 min, and ChIP assays were performed as previously reported. 8 Briefly, equal amounts of isolated chromatin were subjected to immunoprecipitation with anti-SP1, anti-p65, and IgG monoclonal antibodies. Primers with the following sequences were used for the ChIP assays: IKKb, forward 5 0 -CACGGTCTGTCTA CTTTC-3 0 and reverse 5 0 -CTGCTCTGACGTCACGGA-3 0 ; TWIST1, forward 5 0 -GGTACCACTTCGAAAAGTCCCTCCT CCTC-3 0 and reverse 5 0 -CTCGAGTGGGCGAGAGCTGCA GACTTGG-3 0 .
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay
This analysis was conducted as previously reported.
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Annexin V-binding assay for apoptosis
After cells were exposed to cisplatin or paclitaxel, the degree of apoptosis was measured using an Annexin V Apoptosis Detection Kit, according to the protocols of the manufacturer (BD Pharmingen, Bedford, MA). The harvested cell suspension was incubated with annexin V for 15 min at room temperature in the dark and then analyzed by flow cytometry.
Statistics
Data were analyzed using the Statistical Package for the Social Sciences software program (version 17.0; SPSS Inc., Chicago, IL, USA). Interval variables are shown as mean 6 standard errors of mean; the differences between groups were analyzed using the Mann-Whitney U test. The receiver operating characteristic curve-determined cut-off value was optimized for diagnostic sensitivity and specificity for the prediction of progression or death. Frequency distributions between categorical variables were compared using Pearson's chi-squared test and
Fisher's exact method. Survival was estimated using the Kaplan-Meier method and results were compared by performing log-rank tests. p Values < 0.05 (2-sided) were considered significant.
Results
COL11A1 regulates TWIST1 expression and chemosensitivity
To examine whether TWIST1 expression could be regulated by COL11A1 in ovarian cancer cells, ES-2 and TOV-21G cells were transfected with 2 types of short-hairpin RNAs targeting COL11A1, while A2780 and OVCAR-4 cells were transfected with a COL11A1 cDNA plasmid. As expected, TWIST1 mRNA and protein expression were reduced in COL11A1-knockdown cells (Fig. 1a) and elevated in COL11A1-overexpressing cells (Fig. 1b) . COL11A1-knockdown ES-2 and COL11A1-overexpressing A2780 cells were further treated by ectopically expressing and silencing TWIST1, respectively to clarify whether COL11A1-mediated TWIST1 could be responsible for cisplatin and paclitaxel resistance. The chemosensitivity to cisplatin increased in COL11A1-knockdown ES-2 cells, which was reinstituted by ectopically expressing TWIST1 in the same cells (Fig. 1c, left panel) . The opposite effect was seen when COL11A1-overexpressing A2780 cells were transfected with shTWIST1 (Fig. 1c, right) . A similar phenomenon was seen with paclitaxel treatment (Fig. 1d) . These results indicated that COL11A1-mediated TWIST1 expression was responsible for cisplatin and paclitaxel resistance in ovarian cancer cells.
TWIST1 overexpression is associated with unfavorable EOC treatment outcome
The mRNA-expression levels of TWIST1 and COL11A1 in samples from 120 patients with EOC are shown in Table 1 . The median follow-up period was 41.6 months (range, 1-65 months). During follow-up, 67 patients (55.8%) experienced cancer progression, and 59 patients (49.2%) died. High TWIST1 mRNA levels were significantly related to high COL11A1-expressing tumors (p < 0.001). In addition, high TWIST1 expression levels significantly associated with a PFI of 6 months (p 5 0.001) and death (p 5 0.040). TWIST1 levels did not differ between patient groups when analyzed according to age, histology, stage, tumor grade and residual tumor size. Patients with poor chemoresponses tended to show higher TWIST1 expression than those with good chemoresponses, although this difference was not statistically significant (72.2% versus 27.8%, p 5 0.058). Patients with high TWIST1 mRNA levels had significantly shorter 5-year OS (p 5 0.004) and PFS (p 5 0.009) rates, compared to those with low TWIST1 levels (Fig. 2) .
IKKb/NF-jB activation was regulated by COL11A1
TWIST1 expression has been shown to be upregulated by IKKb/NF-jB signaling. 13 We thus hypothesized that TWIST1
induction by COL11A1 might be regulated via IKKb/NF-jB activation. First, we examined the relationship between COL11A1 and IKKb expression in a panel of ovarian cancer cells. Western blotting showed that COL11A1 expression positively correlated with IKKb expression (Fig. 3a) . When ES-2 and TOV-21G cells were transfected with 2 different short-hairpin RNAs targeting COL11A1, IKKb expression was reduced at the protein and RNA levels (Fig. 3b) , whereas IKKb protein and RNA-expression levels increased when A2780 and OVCAR-4 cells were transfected with a COL11A1 cDNA plasmid (Fig. 3c) . These results indicated that COL11A1 regulates IKKb expression in ovarian cancer cells. Furthermore, TWIST1 and IjBa phosphorylation increased in COL11A1-overexpressing A2780 cells and decreased in COL11A1-knockdown ES-2 cells. Similarly, an increase in nuclear p65 expression was observed in COL11A1-overexpressing A2780 cells and a decrease in such expression was observed in COL11A1-knockdown ES-2 cells (Fig. 3d) . The use of a luciferase reporter assay further confirmed that COL11A1 overexpression or knockdown in ovarian cancer cells modulated NF-jB reporter activity (Fig. 3e) . Interestingly, the COL11A1-mediated increases of TWIST1 and IKKb expression, IjBa phosphorylation, nuclear p65 levels, and NF- , and the nuclear p65 fraction in whole lysates of both types of cells were evaluated by western blotting. b-actin and SP1 were detected as loading controls for whole-cell lysates and nuclear fractions, respectively. (e) ES-2 cells were transfected with COL11A1 siRNAs and an IKKb cDNA plasmid, and A2780 cells were transfected with a COL11A1 cDNA plasmid and IKKb siRNA. Luciferase activities were measured and normalized to Renilla luciferase activities. All experiments were performed in triplicate. p Values were determined using Student's t test. *p < 0.05 or **p < 0.005, relative to control cells treated with shControl or VC.
jB reporter activity in COL11A1-overexpressing A2780 cells were all reduced by transfecting a short-hairpin RNA against IKKb (shIKKb; Figs. 3d and 3e, right panels) . The opposite effects were seen when COL11A1-knockdown ES-2 cells were transfected with an IKKb-overexpression plasmid (Figs.3d and  3e, left panel) . These results clearly indicated that COL11A1 promotes NF-jB activation by increasing IKKb transcription, which subsequently regulates the induction of TWIST1. 
COL11A1 regulated IKKb transcription via regulating SP1 binding to the IKKb promoter
The direct link between COL11A1 and IKKb has not been previously demonstrated. To further explore the mechanism by which COL11A1 increased IKKb transcription, a fragment spanning positions 2400 to 11 relative to the IKKb transcription start site was amplified by PCR, sequenced, and cloned into a luciferase reporter plasmid. As shown in Figure  4a , the reporter activities of the IKKb promoter upon transfection of the 2400 to 11 fragment in ES-2 and TOV-21G cells were significantly higher than in OVCAR-4, OVCAR-3, and A2780 cells transfected with the same fragment.
Data from a previous study indicated the presence of 2 SP1-binding sites in the IKKb promoter that are responsible for regulating IKKb transcription. 14 We next questioned whether the activation of IKKb expression by COL11A1 might be mediated by increased SP1-binding activity. To address this possibility, the SP1-binding sites in the IKKb promoter were mutated by site-directed mutagenesis. An IKKb (-400/11) promoter with 2 mutated SP1 binding sites had a reporter activity 80% lower than the wild-type promoter, and the reporter activity was reduced by 40% when the IKKb (-400/11) promoter had either one of the SP1-binding sites mutated (Fig. 4b) .
Previous data showed that kinases may phosphorylate SP1, which can subsequently influence SP1 binding to its target gene promoters. 15 Our results showed increased SP1 phosphorylation in COL11A1-overexpressing A2780 cells and decreased SP1 phosphorylation in COL11A1-knockdown ES-2 cells (Fig. 4c, upper panel) . ChIP analysis further indicated that SP1 binding to the IKKb promoter decreased in COL11A1-knockdown ES-2 cells and increased in COL11A1-overexpressing A2780 cells (Fig. 4c, lower panel) . Furthermore, COL11A1-dependent SP1 binding to the IKKb promoter was inhibited by mithramycin A, which blocks SP1 binding to its target gene promoters (Fig. 4d) . These results indicated that SP1 is the major determinant for the COL11A1-mediated increase in IKKb expression and that increased SP1 binding to the IKKb promoter, induced by COL11A1, may occur through kinase activation.
In addition, p65 binding to the TWIST1 promoter decreased in COL11A1-knockdown ES-2 cells and increased in COL11A1-overexpressing A2780 cells (Fig. 4e, upper  panel) . p65 binding to the TWIST1 promoter (Fig. 4e, upper  panel) was affected by IKKb knockdown and overexpression in COL11A1-knockdown ES-2 cells, and the level of reporter activity (Fig. 4e) was affected in COL11A1-overexpressing A2780 cells. There results indicated that COL11A1-dependent TWIST1 induction was mediated by IKKb transcription regulated by SP1 binding to the IKKb promoter.
COL11A1 inhibits apoptosis by increasing NF-jB-mediated TWIST1/Mcl-1 or GAS6 expression
We next explored the possibility that anti-apoptosis genes such as IAP1, IAP2, Bcl-2, Bcl-xL, Mcl-1, BIM, GAS6, and L1CAM are involved in COL11A1-mediated TWIST1 upregulation, which contributes to cisplatin and paclitaxel resistance. Mcl-1 and GAS6 expression were decreased by COL11A1 knockdown in A2780CP70 and ES-2 cells and increased by COL11A1 overexpression in A2780 cells. In contrast, the IAP1, IAP2, Bcl-2, Bcl-xL, BIM, and L1CAM levels remained unchanged following COL11A1 knockdown or overexpression (Fig. 5a and Supporting Information Fig. 1  A) . The TWIST1, Mcl-1, and GAS6 levels in COL11A1-overexpressing A2780 cells were attenuated by transfection of a short-hairpin RNA against TWIST1 (shTWIST1; Fig. 5b and Supporting Information Fig. 1B, right panel) . The opposite effect was seen when COL11A1-knockdown ES-2 cells were transfected with a TWIST1-overexpression plasmid ( Fig.  5b and Supporting Information Fig. 1B, left panel) . Furthermore, the IKKb, TWIST1, Mcl-1, and GAS6 levels in COL11A1-overexpressing A2780 cells were attenuated by transfection of a short-hairpin RNA against IKKb (shIKKb; Fig. 5c and Supporting Information Fig. 1 C, right panel) . The binding activity of p65 to the TWIST1 promoter was evaluated by ChIP in ES-2 cells were transiently transfected with COL11A1 siRNAs and an IKKb cDNA plasmid, and A2780 cells were transfected with a COL11A1 cDNA plasmid and an IKKb siRNA. Chromatin was isolated and immunoprecipitated using an anti-p65 antibody. Lower panel: ES-2 cells were transfected with a COL11A1 siRNAs and an IKKb cDNA plasmid, and A2780 cells were transfected with a COL11A1 cDNA plasmid and IKKb siRNA. TWIST1 mRNA levels and promoter activities were evaluated by performing real-time RT-PCR and luciferase assays, respectively. All experiments were performed in triplicate. P values were determined using Student's t test. *p < 0.05 or **p < 0.005, relative to the control cells treated with shControl or VC.
The opposite effect was seen when COL11A1-knockdown ES-2 cells were transfected with an IKKb-overexpression plasmid ( Fig. 5c and Supporting Information Fig. 1 C, left  panel) . Our results indicated that the Mcl-1 and GAS6 induction by COL11A1 was regulated via IKKb/NF-jB activation.
Annexin V/propidium iodide (PI) staining indicated that cisplatin and paclitaxel-induced cell apoptosis decreased in COL11A1-overexpressing A2780 cells when compared with their control cells (Fig. 5d) . Moreover, the anti-apoptotic effect induced by COL11A1 in COL11A1-overexpressing A2780 cells could be reversed by silencing NF-jB, TWIST1, Mcl-1, and GAS6 expression ( Fig. 5d and Supporting Information Fig. 1 D) . These results suggested that the increase of Mcl-1 and GAS6 expression caused by COL11A1-mediated NF-jB/TWIST1 signaling may be responsible for COL11A1-mediated cisplatin and paclitaxel resistance in ovarian cancer cells.
Previous data showed that TWIST1 promoted chemoresistance in ovarian cancer cells through GAS6, thereby activating Akt. 16 We thus examined the relationship between Akt phosphorylation (p-Akt) and COL11A1/TWIST1 expression. Western blot data showed that p-Akt and the Akt hrs. These cells were treated with 0.1% dimethyl sulfoxide, 10 lM cisplatin, or 0.1 lg/ml paclitaxel for 24 hrs. After incubation, the cells were then subjected to annexin-V and PI staining, followed by flow cytometric analysis. The percentage of apoptotic cells in the annexin-V1/PI-population (early apoptosis) plus annexin-V1/PI1 (late apoptosis/secondary necrosis) was determined by flow cytometry. P values were determined using Student's t test. **p < 0.005, relative to control cells treated with vector. (e) A model illustrating the hypothetical role of COL11A1 in controlling chemoresistance and apoptosis in ovarian cancer cells.
activator phosphoinositide-dependent kinase-1 (PDK1) 7 were not altered by TWIST1 knockdown or overexpression (Fig. 5b) .
The human copper transporter 1 (hCTR1) has been reported to mediate the uptake of cisplatin in cultured cells 17 and is associated with responsiveness to platinum-based therapy in human ovarian tumors. 18 We thus determined the relationship between hCTR1 and COL11A1/TWIST1. Western blot data showed that hCTR1 expression was not altered by either COL11A1 knockdown or overexpression (Fig. 5b) .
Discussion
Our previous report indicated that COL11A1 and TWIST1 were the most differentially upregulated genes in chemoresistant ovarian tumors. 7 Here, we further characterized TWIST1 as a candidate biomarker of chemoresistance in ovarian cancer. The principal finding of our study is that EOC patients with TWIST1 overexpression had a higher rate of resistance to chemotherapy and shorter survival after firstline platinum-based regimens, indicating that elevated TWIST1 expression is an important marker of chemoresistance and poor prognosis. We also found that an increase in TWIST1 expression caused by COL11A1-upregulated IKKb transcription was achieved by increased phosphorylation and binding of SP1 to the IKKb promoter. COL11A1-mediated NF-jB activation, via the activation of IKKb transcription, promoted TWIST1 and Mcl-1 expression, which was associated with chemoresistance and apoptosis inhibition (Fig. 5e) .
NF-jB is a sequence-specific transcription factor that responds to multiple cell-signaling pathways through the transcriptional regulation of target genes involved in cell survival. 19, 20 NF-jB is active in the nucleus and is maintained in an inactive state by sequestration in a cytoplasmic complex with IjBa. NF-jB activation is not only involved in cancer development, 19 but also can function as a tumor suppressor. [21] [22] [23] NF-jB activity can be pro-apoptotic, can suppress metastasis, or can inhibit proliferation. 22 In contrast, through the activation of survival pathways, NF-jB suppresses apoptosis when cancer cells are exposed to radiotherapy or chemotherapy, thus contributing to resistance. [24] [25] [26] [27] [28] [29] [30] [31] In this study, we showed that COL11A1 conferred chemoresistance through NF-jB-mediated TWIST1 expression in ovarian cancer cells. These findings are consistent with previous data showing that TWIST1 upregulation by NF-jB inhibits daunorubicin-induced cytotoxicity. 32 We further provide evidence that COL11A1-regulated, IKKb/NF-jB-mediated chemoresistance is modulated by SP1 phosphorylation and binding to the IKKb promoter. To the best of our knowledge, this is the first report to link COL11A1 and IKKb expression. Our results showed that COL11A1 upregulated SP1 phosphorylation and enhanced SP1 binding to the IKKb promoter (Figs. 4c and 4d) . Thus, we propose that increased SP1 binding to the IKKb promoter induced by COL11A1 may occur through kinase activation. Further research is needed to explore which kinase might be activated by COL11A1 to promote increased SP1 binding to the IKKb promoter.
TWIST1 promotes resistance to apoptosis when cells are challenged with cisplatin in lung, 33, 34 bladder, 35 and ovarian cancer, 12, 36, 37 or paclitaxel in ovarian and prostate cancers. 11, 38, 39 Here, we observed that COL11A1 interfered with cisplatin and paclitaxel-induced apoptosis in ovarian cancer cells by upregulating NF-jB/TWIST1-mediated Mcl-1 and GAS6 expression. Mcl-1 has been shown to be a critical survival factor in ovarian cancer. [40] [41] [42] Previous findings also indicated that TWIST1 knockdown enhances the sensitivity of cells to cisplatin through Mcl-1 downregulation, which is linked to inhibited mTOR activity in lung cancer cells. 34 GAS6 is known to inhibit apoptosis and GAS6 upregulation is a marker for poor prognosis in ovarian cancer. 16 Our results suggest that Mcl-1 and GAS6 downregulation plays an important role in the sensitizing effect of TWIST1 siRNA on chemotherapeutic drug-induced cell death.
The cytotoxicity of chemotherapeutic agents in cancer cells is dependent on their rates of uptake and extrusion. It was demonstrated that hCTR1, which is involved in the maintenance of copper homeostasis, is also involved in the transport of platinum 15 and has a role in platinum resistance. 43 , 44 We previously showed that FOXM1 may confer cisplatin resistance by inhibiting hCTR1 expression. 45 Our data also showed that knockdown of RNA-binding proteins (U3 small nucleolar ribonucleoprotein protein IMP3 or Lin-28 homolog B) increased the platinum sensitivity, but not the paclitaxel sensitivity, of ovarian cancer cells through increased hCTR1 expression. 46 However, in this study, we did not observe a significant role of hCTR1 in COL11A1-mediated chemoresistance. This result further suggests that the effects of COL11A1 on cisplatin or paclitaxel uptake may depend on different transporters. Further investigation is required to explore the exact mechanisms by which resistance to cisplatin or paclitaxel is regulated by COL11A1.
In summary, the mechanistic results of this study show that COL11A1 can upregulate IKKb transcription to constitutively activate the NF-jB-signaling pathway by increasing the SP1 DNA-binding activity, thereby promoting TWIST1 and Mcl-1 expression, which were associated with chemoresistance and apoptosis inhibition. Owing to its central role in NF-jB activation, IKK has been a major molecular target for NF-jB inhibition, and clinical trials targeting NF-jB are currently under investigation. 47 We suggest that IKKb and TWIST1 can potentially be targeted in patients with COL11A1-positive ovarian cancer.
